REVAMP TT 

Randomized controlled trial of the effect of intravenous iron on anaemia in Malawian pregnant women (REVAMP): Third Trimester

Start and End dates: 2020 to 2024

Source of Funding: Bill & Melinda Gates Foundation ($4.6 million)

This is an open-label clinical trial assessing the effectiveness and safety of intravenous iron, namely ferric carboxymaltose and isomaltoside versus oral iron pills in the prevention of anaemia in pregnant women in their third trimester. This study is recruiting and following up 300 pregnant women until they deliver and their infants until 12 months of age in Zomba, Malawi.